CIK: 0001574661
Total reported value
$16.0M
Reporting period: 2016-09-30 · Number of holdings: 11
March Altus Capital Management LP disclosed 11 holdings in its latest 13F filing for the period ending 2016-09-30, with total reported value of $16.0M and a quarterly turnover rate of 63.9%.
Browse other institutions with under $100M AUMBrowse other institutions starting with "M"
March Altus Capital Management LP's disclosed holdings carry a Herfindahl concentration index of 0.137 — mathematically equivalent to about 7 equally-sized positions, close to its 11 actual disclosed holdings. Value is spread relatively evenly across the portfolio rather than concentrated in a handful of names.
Position sizes are fairly uniform across the portfolio (a coefficient of variation of 0.75), suggesting a disciplined, rules-based approach to how much capital goes into each idea.
Recent activity leans toward adding more aggressively to already-large existing positions than to newly initiated ones (a 6.3 percentage-point tilt) — a pattern consistent with a momentum-following approach.
Sector classification currently covers about 25% of this portfolio's disclosed value; the remainder includes holdings (e.g. unmapped tickers, options, or other security types) not yet covered by our sector mapping.
Add EW
+86.0% $2.3M
Trim LLY
-50.4% -$1.0M
Trim ACAD
-12.1% -$372.0K
Trim ALXN
-27.9% -$244.0K
Trim JNJ
0.0% -$41.0K
Add PETXEUR
0.0% $664.0K
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | EW | Edwards Lifesciences CORP | Stock-Healthcare | 26.11% | +11.76% | +85.97% | |
| 2 | ACAD | Acadia Pharmaceuticals INC | Stock-Healthcare | 14.47% | -6.28% | -12.09% | |
| 3 | PETXEUR | Aratana Therapeutics INC | Stock-Other | 12.79% | +2.12% | — | |
| 4 | JNJ | Johnson & Johnson | Stock-Healthcare | 9.61% | -2.58% | — | |
| 5 | DXCM | Dexcom INC | Stock-Healthcare | 7.79% | +0.62% | +21.37% | |
| 6 | LLY | Eli Lilly & Co | Stock-Healthcare | 6.68% | -9.64% | -50.35% | |
| 7 | T8S | Tesaro INC | Stock-Other | 6.27% | +6.27% | NEW | |
| 8 | ZTS | Zoetis INC | Stock-Healthcare | 5.17% | +5.17% | NEW | |
| 9 | BIIB | Biogen INC | Stock-Healthcare | 5.09% | +5.09% | NEW | |
| 10 | ALXN | Alexion Pharmaceuticals INC | Stock-Other | 4.75% | -3.01% | -27.91% | |
| 11 | REGN | Regeneron Pharmaceuticals | Stock-Healthcare | 1.26% | +1.26% | NEW |
Not enough priced holdings yet to compute performance
| Period | Holdings | Total value | Stability | Top holdings |
|---|---|---|---|---|
| 2016-09-30 | 11 | $16.0M | 64 | |
| 2016-06-30 | 8 | $12.9M | 65 | |
| 2016-03-31 | 9 | $9.7M | 66 | |
| 2015-12-31 | 10 | $10.9M | 100 | |
| 2015-09-30 | 14 | $17.0M | 100 | |
| 2015-06-30 | 20 | $17.2M | 50 | |
| 2015-03-31 | 15 | $15.9M | 100 | |
| 2014-12-31 | 23 | $219.0M | 97 | |
| 2014-09-30 | 25 | $251.3M | 57 | |
| 2014-06-30 | 31 | $272.9M | 100 | |
| 2014-03-31 | 28 | $311.5M | 68 | |
| 2013-12-31 | 28 | $330.2M | 0 |
March Altus Capital Management LP's most significant position changes for 2016-09-30: Sold out: Align Technology INC (ALGN); New buy: Tesaro INC (T8S); New buy: Zoetis INC (ZTS); New buy: Biogen INC (BIIB); New buy: Regeneron Pharmaceuticals (REGN).
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | EW | Edwards Lifesciences CORP | +11.8% | +85.97% | Add |
| 2 | PETXEUR | Aratana Therapeutics INC | +2.1% | — | Unchanged |
| 3 | DXCM | Dexcom INC | +0.6% | +21.37% | Add |
| 4 | JNJ | Johnson & Johnson | -2.6% | — | Unchanged |
| 5 | ALXN | Alexion Pharmaceuticals INC | -3% | -27.91% | Trim |
| 6 | ACAD | Acadia Pharmaceuticals INC | -6.3% | -12.09% | Trim |
| 7 | LLY | Eli Lilly & Co | -9.6% | -50.35% | Trim |
| 8 | ALGN | Align Technology INC | — | EXIT | Sold out |
| 9 | T8S | Tesaro INC | — | NEW | New buy |
| 10 | ZTS | Zoetis INC | — | NEW | New buy |
| 11 | BIIB | Biogen INC | — | NEW | New buy |
| 12 | REGN | Regeneron Pharmaceuticals | — | NEW | New buy |
| Period | Filed | Type | EDGAR |
|---|---|---|---|
| 2016-09-30 | 2016-11-07 | 13F-HR | View on EDGAR |
| 2016-06-30 | 2016-07-27 | 13F-HR | View on EDGAR |
| 2016-03-31 | 2016-05-12 | 13F-HR | View on EDGAR |
| 2015-12-31 | 2016-02-16 | 13F-HR | View on EDGAR |
| 2015-09-30 | 2015-11-16 | 13F-HR | View on EDGAR |
| 2015-06-30 | 2015-08-14 | 13F-HR | View on EDGAR |
| 2015-03-31 | 2015-05-15 | 13F-HR | View on EDGAR |
| 2014-12-31 | 2015-02-17 | 13F-HR | View on EDGAR |
| 2014-09-30 | 2014-11-14 | 13F-HR | View on EDGAR |
| 2014-06-30 | 2014-08-14 | 13F-HR | View on EDGAR |
| 2014-03-31 | 2014-05-15 | 13F-HR | View on EDGAR |
| 2013-12-31 | 2014-02-14 | 13F-HR | View on EDGAR |
Institutions with a similar AUM
CIK 0001540951
Total reported value
$16.0M
1 stks
2026-03-31
AUM within 0.1% of this institution
CIK 0001701880
Total reported value
$16.1M
1 stks
2020-09-30
Stale — no recent filing
AUM within 0.6% of this institution
CIK 0001080381
Total reported value
$16.1M
58 stks
2022-09-30
Stale — no recent filing
AUM within 0.7% of this institution
Institutions with overlapping top holdings
CIK 0000012933
Total reported value
$622.0M
398 stks
2022-12-31
Stale — no recent filing
1 of the top 5 holdings overlap, including Johnson & Johnson
CIK 0000312955
Total reported value
$372.6M
165 stks
2018-12-31
Stale — no recent filing
1 of the top 5 holdings overlap, including Johnson & Johnson
CIK 0000315032
Total reported value
$126.9B
197 stks
2026-03-31
1 of the top 5 holdings overlap, including Johnson & Johnson